NASDAQ:RZLT Rezolute (RZLT) Stock Price, News & Analysis → Catalyst Could Trigger 10,000% Crypto Gains (From Crypto 101 Media) (Ad) Free RZLT Stock Alerts $3.88 +0.03 (+0.78%) (As of 12:59 PM ET) Add Compare Share Share Today's Range$3.80▼$4.0050-Day Range$2.42▼$5.7952-Week Range$0.72▼$6.10Volume318,680 shsAverage Volume497,987 shsMarket Capitalization$155.70 millionP/E RatioN/ADividend YieldN/APrice Target$9.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Rezolute alerts: Email Address Rezolute MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside141.7% Upside$9.67 Price TargetShort InterestHealthy2.03% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.98Based on 12 Articles This WeekInsider TradingAcquiring Shares$201,607 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($1.15) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.79 out of 5 starsMedical Sector218th out of 913 stocksPharmaceutical Preparations Industry96th out of 430 stocks 4.5 Analyst's Opinion Consensus RatingRezolute has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRezolute has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Rezolute's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.03% of the outstanding shares of Rezolute have been sold short.Short Interest Ratio / Days to CoverRezolute has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rezolute has recently increased by 162.01%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldRezolute does not currently pay a dividend.Dividend GrowthRezolute does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RZLT. Previous Next 3.3 News and Social Media Coverage News SentimentRezolute has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Rezolute this week, compared to 1 article on an average week.Search Interest8 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 14% compared to the previous 30 days.MarketBeat Follows9 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days. Previous Next 5.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rezolute insiders have bought more of their company's stock than they have sold. Specifically, they have bought $201,607.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.80% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rezolute's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Rezolute are expected to decrease in the coming year, from ($1.15) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rezolute is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rezolute is -3.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRezolute has a P/B Ratio of 1.27. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Rezolute's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Insiders Exposed917 Trades… Zero Losses?If you want to learn how A Group of traders Made 917 Trades Without A Single Loss! And How You Could Have Consistently Beat the Market by following them...Just click this link and follow along About Rezolute Stock (NASDAQ:RZLT)Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Read More RZLT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RZLT Stock News HeadlinesJune 15 at 9:35 AM | insidertrades.comBrian Kenneth Roberts Purchases 4,300 Shares of Rezolute, Inc. (NASDAQ:RZLT) StockMay 29, 2024 | insidertrades.comRezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Buys 7,500 SharesJune 18, 2024 | DTI (Ad)There’s only one solution to the impending energy catastrophe… Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! June 16 at 5:38 AM | americanbankingnews.comInsider Buying: Rezolute, Inc. (NASDAQ:RZLT) CFO Buys 40,000 Shares of StockJune 15 at 10:40 AM | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Insider Brian Kenneth Roberts Purchases 4,300 Shares of StockJune 13, 2024 | globenewswire.comRezolute Announces Pricing of Public Offering of $60 Million of Common Stock and Pre-Funded WarrantsJune 13, 2024 | globenewswire.comRezolute Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsJune 13, 2024 | americanbankingnews.comShort Interest in Rezolute, Inc. (NASDAQ:RZLT) Rises By 162.0%June 18, 2024 | DTI (Ad)There’s only one solution to the impending energy catastrophe… Folks, it's 2024… Things that we used to rely on - are failing us. Take the phasing out of fossil fuels… Matched with the destruction of oil refineries around the world… And the outright failure of solar and wind technologies… But there is just one solution… And right now governments around the world are stockpiling this resource at the fastest rate in DECADES! May 30, 2024 | globenewswire.comRezolute to Participate in the Jefferies Global Healthcare ConferenceMay 22, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 22, 2024 | msn.comWhy Is Small-Cap Metabolic-Focused Rezolute Stock Trading Higher On Wednesday?May 22, 2024 | markets.businessinsider.comRezolute’s RZ402 Shows Promising Efficacy and Safety in DME Treatment, Reinforcing Buy RatingMay 21, 2024 | globenewswire.comRezolute Reports Positive Topline Results from Phase 2 Proof of Concept Study of RZ402 in Patients with Diabetic Macular Edema (DME)May 17, 2024 | markets.businessinsider.comBuy Rating on Rezolute: Unrecognized Potential in DME Treatment and Advancements in RZ358 for HyperinsulinismMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Rezolute’s Solid Financials and Advancing Clinical TrialsMay 16, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rezolute Amidst Clinical Progress and Market OpportunityMay 16, 2024 | finanznachrichten.deRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 16, 2024 | investorplace.comRZLT Stock Earnings: Rezolute Misses EPS for Q3 2024May 15, 2024 | globenewswire.comRezolute Reports Third Quarter Fiscal 2024 Financial Results and Provides Business UpdateMay 12, 2024 | nasdaq.comRezolute, Inc. Common Stock (NV) (RZLT) NewsMay 10, 2024 | finance.yahoo.comRezolute, Inc. (NASDAQ:RZLT) has caught the attention of institutional investors who hold a sizeable 47% stakeApril 23, 2024 | globenewswire.comPhase 2 RIZE Study Sub-Analyses to be Presented at the 2024 Pediatric Endocrine Society Annual MeetingApril 19, 2024 | msn.comJonesTrading Initiates Coverage of Rezolute (RZLT) with Buy RecommendationApril 18, 2024 | markets.businessinsider.comOptimistic Buy Rating for Rezolute’s RZ402 Drug Candidate Amid Promising DME Treatment ProspectsApril 15, 2024 | investorplace.comCan You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?April 10, 2024 | benzinga.comRezolute Stock (NASDAQ:RZLT), Analyst Ratings, Price Targets, PredictionsSee More Headlines Receive RZLT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rezolute and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today6/18/2024Fiscal Year End6/30/2024Next Earnings (Estimated)9/12/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RZLT CUSIPN/A CIK1509261 Webwww.rezolutebio.com Phone(650) 206-4507FaxN/AEmployees57Year FoundedN/APrice Target and Rating Average Stock Price Target$9.67 High Stock Price Target$14.00 Low Stock Price Target$5.00 Potential Upside/Downside+151.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-51,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-60.90% Return on Assets-54.58% Debt Debt-to-Equity RatioN/A Current Ratio11.82 Quick Ratio11.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.15 per share Price / Book1.22Miscellaneous Outstanding Shares40,135,000Free Float31,787,000Market Cap$154.52 million OptionableOptionable Beta1.30 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesMr. Nevan Charles Elam J.D. (Age 57)Founder, CEO & Acting Chairman of the Board Comp: $973.65kDr. Brian Kenneth Roberts M.D. (Age 49)Chief Medical Officer Comp: $738.86kMr. Daron G. Evans M.B.A. (Age 50)M.S., Chief Financial Officer Dr. Davelyn Eaves Hood M.B.A.M.D., Director and Head of Scientific & Patient AffairsMr. Michael R. DeperroSenior VP & Head of Corporate DevelopmentMr. Michael CovarrubiasSenior VP & Head of Program & Portfolio ManagementMr. Chris MilksVP & Head of FinanceDr. Raj Agrawal M.D.VP & Head of Ophthalmological Clinical DevelopmentMs. Robyn SweinhartVP & Head of QualityMs. Erin O'BoyleSenior VP & Head of Clinical OperationsMore ExecutivesKey CompetitorsLifeVantageNASDAQ:LFVNXeris BiopharmaNASDAQ:XERSKalVista PharmaceuticalsNASDAQ:KALVAVEO PharmaceuticalsNASDAQ:AVEOZealand Pharma A/SNASDAQ:ZEALView All CompetitorsInsiders & InstitutionsBrian Kenneth RobertsBought 4,300 shares on 6/14/2024Total: $16,813.00 ($3.91/share)Daron EvansBought 40,000 shares on 6/14/2024Total: $161,600.00 ($4.04/share)Daron EvansBought 451 shares on 5/29/2024Total: $1,578.50 ($3.50/share)Brian Kenneth RobertsBought 7,500 shares on 5/23/2024Total: $20,175.00 ($2.69/share)Daron EvansBought 58 shares on 5/23/2024Total: $165.30 ($2.85/share)View All Insider TransactionsView All Institutional Transactions RZLT Stock Analysis - Frequently Asked Questions Should I buy or sell Rezolute stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Rezolute in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RZLT shares. View RZLT analyst ratings or view top-rated stocks. What is Rezolute's stock price target for 2024? 6 Wall Street analysts have issued 12-month target prices for Rezolute's shares. Their RZLT share price targets range from $5.00 to $14.00. On average, they predict the company's stock price to reach $9.67 in the next year. This suggests a possible upside of 141.7% from the stock's current price. View analysts price targets for RZLT or view top-rated stocks among Wall Street analysts. How have RZLT shares performed in 2024? Rezolute's stock was trading at $0.9925 at the start of the year. Since then, RZLT stock has increased by 303.0% and is now trading at $4.00. View the best growth stocks for 2024 here. Are investors shorting Rezolute? Rezolute saw a increase in short interest in the month of May. As of May 31st, there was short interest totaling 814,600 shares, an increase of 162.0% from the May 15th total of 310,900 shares. Based on an average daily volume of 571,100 shares, the short-interest ratio is currently 1.4 days. View Rezolute's Short Interest. When is Rezolute's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, September 12th 2024. View our RZLT earnings forecast. How were Rezolute's earnings last quarter? Rezolute, Inc. (NASDAQ:RZLT) announced its quarterly earnings results on Wednesday, May, 15th. The company reported ($0.34) earnings per share for the quarter, hitting the consensus estimate of ($0.34). What other stocks do shareholders of Rezolute own? Based on aggregate information from My MarketBeat watchlists, some companies that other Rezolute investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Acasti Pharma (ACST), CymaBay Therapeutics (CBAY), Entasis Therapeutics (ETTX), Akero Therapeutics (AKRO), Cumberland Pharmaceuticals (CPIX), Evofem Biosciences (EVFM) and Evelo Biosciences (EVLO). Who are Rezolute's major shareholders? Rezolute's stock is owned by a variety of institutional and retail investors. Top institutional investors include Vivo Capital LLC (6.97%), Affinity Asset Advisors LLC (3.99%), Vanguard Group Inc. (3.87%), Rosalind Advisors Inc. (0.50%), Acadian Asset Management LLC (0.23%) and Virtu Financial LLC (0.04%). Insiders that own company stock include Brian Kenneth Roberts, Daron Evans, Genexine Inc, Gil M Labrucherie, Nevan C Elam and Young-Jin Kim. View institutional ownership trends. How do I buy shares of Rezolute? Shares of RZLT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RZLT) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBiden Nomination CANCELED?And I believe when they do take the oath of office, their fingers will be crossed… and America will descend in...The Freeport Society | SponsoredAvoid These AI Stocks Like the Plague...Artificial intelligence stocks are carrying the market. One of them, Nvidia, recently became the seventh co...Weiss Ratings | SponsoredHe Is Giving Away BitcoinAnd my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a v...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rezolute, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rezolute With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.